High-Efficiency Transduction of Fibroblasts and Mesenchymal Stem Cells by Tyrosine-Mutant AAV2 Vectors for Their Potential Use in Cellular Therapy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus 2 (AAV2) vectors transduce fibroblasts and mesenchymal stem cells (MSCs) inefficiently, which limits their potential widespread applicability in combinatorial gene and cell therapy. We have reported that AAV2 vectors fail to traffic efficiently to the nucleus in murine fibroblasts. We have also reported that site-directed mutagenesis of surface-exposed tyrosine residues on viral capsids leads to improved intracellular trafficking of the mutant vectors, and the transduction efficiency of the single tyrosine-mutant vectors is ∼10-fold higher in human cells. In the current studies, we evaluated the transduction efficiency of single as well as multiple tyrosine-mutant AAV2 vectors in murine fibroblasts. Our results indicate that the Y444F mutant vectors transduce these cells most efficiently among the seven single-mutant vectors, with >30-fold increase in transgene expression compared with the wild-type vectors. When the Y444F mutation is combined with additional mutations (Y500F and Y730F), the transduction efficiency of the triple-mutant vectors is increased by ∼130-fold and the viral intracellular trafficking is also significant improved. Similarly, the triple-mutant vectors are capable of transducing up to 80–90% of bone marrow-derived primary murine as well as human MSCs. Thus, high-efficiency transduction of fibroblasts with reprogramming genes to generate induced pluripotent stem cells, and the MSCs for delivering therapeutic genes, should now be feasible with the tyrosine-mutant AAV vectors. Overview Summary Fibroblasts and mesenchymal stem cells (MSCs) are promising targets for gene and cell therapy. Recombinant adeno-associated virus 2 (AAV2) vectors are currently in use in several Phase I/II clinical trials for gene therapy. However, the existing data show that AAV2 vector-mediated transduction of fibroblasts and MSCs is inefficient. We observed that AAV2 vectors containing mutations in three surface-exposed tyrosine residues significantly increase transduction efficiency in fibroblasts, as well as in both human and murine primary MSCs. The increased transduction efficiency of these triple-mutant AAV2 vectors correlates well with improved viral intracellular trafficking in fibroblasts. These data provide strong evidence that high-efficiency gene delivery and transgene expression by AAV vectors are indeed feasible, which should facilitate the generation of induced pluripotent stem cells, as well as the use of MSCs in combinatorial gene and cell therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“Thus, development of alternative vector systems, such as adeno-associated virus (AAV), needs to be pursued, given the proven safety of AAV vectors in several Phase I/II clinical trials (Bainbridge et al. , 2008; Cideciyan et al. , 2008; Hauswirth et al. , 2008; Maguire et al. , 2008).”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“Thus, development of alternative vector systems, such as adeno-associated virus (AAV), needs to be pursued, given the proven safety of AAV vectors in several Phase I/II clinical trials (Bainbridge et al. , 2008; Cideciyan et al. , 2008; Hauswirth et al. , 2008; Maguire et al. , 2008).”
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 2×
“Thus, development of alternative vector systems, such as adeno-associated virus (AAV), needs to be pursued, given the proven safety of AAV vectors in several Phase I/II clinical trials (Bainbridge et al. , 2008; Cideciyan et al. , 2008; Hauswirth et al. , 2008; Maguire et al. , 2008).”
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“The availability of a large repertoire of multiple tyrosine-mutant AAV2 vectors and other AAV serotypes (AAV1–AAV12) (Daya and Berns, 2008) offers hope for achieving 100% transduction at reduced vector doses in the therapeutically important fibroblasts and MSCs.”
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Induced Pluripotent Stem Cell Generation Using a Single Lentiviral Stem Cell Cassette
Sommer, C. A., Stadtfeld, M., Murphy, G. J., Hochedlinger, K., Kotton, D. N., & Mostoslavsky, G. (2009) · Stem Cells · doi:10.1634/stemcells.2008-1075 · Cited by 676 · cited 1×
“…al. , 2002; Lee et al. , 2004; Reiser et al. , 2005; Barzilay et al. , 2009; Jacome et al. , 2009) or in deriving iPS cells from adult somatic cells (Welstead et al. , 2008; Sommer et al. , 2009) and the subsequent use of gene-modified iPS cells for therapeutic globin gene transfer (Townes, 2008).”
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 10×
“It is interesting to note that the tyrosine-mutant efficacy data from NIH 3T3 cells are different from our previously published data with HeLa cells (Zhong et al. , 2008b), where the Y730F mutant was the most efficacious ( * 11-fold higher transduction efficiency vs. the WT vector) (Fig.”
InfluentialSelf-citationHuman fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443 · cited 1×
“Even in cells that allow infection, the level of infection or transgene expression is variable due to well-documented impediments in virus–host cell interactions during the life cycle of AAV2 (Qing et al. , 1999, 2001; Hansen et al. , 2000, 2001a; Zhong et al. , 2006).”
Self-citationGenetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Zhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232 · cited 10×
“It is interesting to note that the tyrosine-mutant efficacy data from NIH 3T3 cells are different from our previously published data with HeLa cells (Zhong et al. , 2008b), where the Y730F mutant was the most efficacious ( * 11-fold higher transduction efficiency vs. the WT vector) (Fig.”
InfluentialSelf-citationMarkusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131 · cited 1×
“8A, the transduction effi-ciency of the Y500F and Y730F vectors was * 3–10-fold higher than that of the WT vector, consistent with our previous studies (Zhong et al. , 2008b), as well as those described by Markusic et al. (2010).”
Self-citationHansen, J., Qing, K., & Srivastava, A. (2001) · Journal of Virology · doi:10.1128/jvi.75.9.4080-4090.2001 · Cited by 129 · cited 4×
“Low-M r DNA was isolated by the method described previously (Hansen et al. , 2000, 2001a; Zhong et al. , 2004), and AAV genomes were electrophoresed on 1% agarose gels and analyzed by Southern blot hybridization using a 32 P-labeled EGFP-specific DNA probe as described above.”
InfluentialSelf-citationQing, K., Hansen, J., Weigel-Kelley, K. A., Tan, M., Zhou, S., & Srivastava, A. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.8968-8976.2001 · Cited by 126 · cited 1×
“Even in cells that allow infection, the level of infection or transgene expression is variable due to well-documented impediments in virus–host cell interactions during the life cycle of AAV2 (Qing et al. , 1999, 2001; Hansen et al. , 2000, 2001a; Zhong et al. , 2006).”
Self-citation
Cited by
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Self-citationCRISPR/Cas9‐mediated genome engineering: An adeno‐associated viral (AAV) vector toolbox
Senís, E., Fatouros, C., Große, S., Wiedtke, E., Niopek, D., Mueller, A., Börner, K., & Grimm, D. (2014) · Biotechnology Journal · doi:10.1002/biot.201400046 · Cited by 260
Weinmann, J., Weis, S., Sippel, J., Tulalamba, W., Remes, A., El Andari, J., Herrmann, A.-K., Pham, Q. H., Borowski, C., Hille, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19230-w · Cited by 259
Intracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258
Metadata
- Authors
- Li, M., Jayandharan, G. R., Li, B., Ling, C., Ma, W., Srivastava, A., & Zhong, L.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2010-11
- Volume
- 21
- Issue
- 11
- Pages
- 1527-1543
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2071714774
- Cited by
- 67
- References
- 13
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.